Once daily immediate-and extended-release bilayer tablets of etoricoxib: A study on the release kinetics

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Objective: In the present work, the main objective was to develop bilayer extended release matrix tablets of etoricoxib by providing a loading dose followed by maintenance dose that expected to improve the therapeutic efficacy of the medication with less toxic effect. Methods: Bilayer tablets of etoricoxib was developed successfully with the meticulous proportion of release controlling Hydroxy propyl methyl cellulose K100 (HPMC K100) and lactose. The tablets were prepared by wet granulation technique. Granules for immediate layer and extended layer for different formulations were prepared separately. The formulations were developed and evaluations were performed to examine the parameters that affect the in vitro performance of the tablets. The drug-excipient compatibility was ensured by Fourier transform infrared spectroscopy (FTIR) study. Results: The values of physical parameters of all formulations were found within appreciable limit. Formulation containing HPMC K 100 and lactose in the proportion of 2:1 in the extended release layer was able to release 26.22% of drug in 15 min and shown a steady release of drug for an extended period of 12 h. The dissolution data was put in Korsemeyer–Peppas model in order to find out n value, which describes the drug release mechanism. The n-value of different formulations were found to be variable. The Fourier transform infrared spectroscopy (FTIR) study revealed absence of any other new peaks and also no differences in the positions of the absorption bands in the bilayer tablet F8 that indicate the lack of significant interactions between etoricoxib and other excipients. Conclusion: It had been concluded that once daily immediate-and extended release bilayer tablet of etoricoxib can be formulated with profound physical characteristics and dissolution properties. This resulted in reducing the daily dose and thus minimise the cardiovascular toxicity of etoricoxib.

References Powered by Scopus

129Citations
N/AReaders
Get full text

Review of bilayer tablet technology

88Citations
N/AReaders
Get full text

Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers

85Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Analytical Quality by Design-Based Robust RP-HPLC Method for Quantitative Estimation of Pregabalin and Etoricoxib in Fixed-Dose Combination Tablet Formulation

13Citations
N/AReaders
Get full text

A Critical Review on Analytical Methods for Recently Approved FDC Drugs: Pregabalin and Etoricoxib

13Citations
N/AReaders
Get full text

Development of sustained release alogliptin tablets using a multiparticulates system made of bentonite

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Mishra, B., & Mohanty, B. (2019). Once daily immediate-and extended-release bilayer tablets of etoricoxib: A study on the release kinetics. International Journal of Applied Pharmaceutics, 11(5), 230–235. https://doi.org/10.22159/ijap.2019v11i5.31638

Readers' Seniority

Tooltip

Lecturer / Post doc 2

50%

PhD / Post grad / Masters / Doc 2

50%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 4

100%

Save time finding and organizing research with Mendeley

Sign up for free